Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study

<h4>Background/Objectives</h4> <p>Treatment of subjects with non-alcoholic fatty liver disease (NAFLD) with omega-3 polyunsaturated fatty acids (PUFA) suggests high levels of docosahexaenoic acid (DHA) tissue enrichment decrease liver fat content. We assessed whether changes in e...

Bibliografski detalji
Glavni autori:	Hodson, L, Bhatia, L, Scorletti, E, Smith, D, Jackson, N, Shojaee-Moradie, F, Umpleby, M, Calder, P, Byrne, C
Format:	Journal article
Izdano:	Nature Publishing Group 2017

Slični predmeti

Whole-body and hepatic dietary fatty acid oxidation is related to postprandial insulin concentrations in people with non-alcoholic fatty liver disease with varying degrees of insulin resistance
od: Hodson, L, i dr.
Izdano: (2013)

The fat mass and obesity-associated (FTO) gene allele rs9939609 and glucose tolerance, hepatic and total insulin sensitivity, in adults with obesity.
od: Ann Kristin Hjelle de Soysa, i dr.
Izdano: (2021-01-01)

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
od: Scorletti, E, i dr.
Izdano: (2014)

Potential benefits of purified long chain omega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and Type 2 diabetes? Results from the WELCOME study
od: Scorletti, E, i dr.
Izdano: (2014)

Measurement of hepatic insulin sensitivity early after the bypass of the proximal small bowel in humans
od: A. D. Miras, i dr.
Izdano: (2017-03-01)

Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis
od: Geraldine F. Clough, i dr.
Izdano: (2020-06-01)

Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?
od: George Kunos, i dr.
Izdano: (2022-01-01)

Circulating docosahexaenoic acid levels are associated with fetal insulin sensitivity.
od: Jin-Ping Zhao, i dr.
Izdano: (2014-01-01)

Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men
od: Pramfalk, C, i dr.
Izdano: (2015)

The new hepatic steatosis nomenclature. No more NAFLD!
od: G.E. Castro-Narro, i dr.
Izdano: (2024-04-01)

Distinct Hepatic Gene‐Expression Patterns of NAFLD in Patients With Obesity
od: Subudhi, Sonu, i dr.
Izdano: (2022)

Distinct Hepatic Gene‐Expression Patterns of NAFLD in Patients With Obesity
od: Sonu Subudhi, i dr.
Izdano: (2022-01-01)

Ethnic differences in beta cell function occur independently of insulin sensitivity and pancreatic fat in black and white men
od: Stephanie A Amiel, i dr.
Izdano: (2021-03-01)

Hepatic iron is the major determinant of serum ferritin in NAFLD patients.
od: Ryan, J, i dr.
Izdano: (2017)

Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD
od: Josh Bilson, i dr.
Izdano: (2021-10-01)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
od: Hirokazu Takahashi, i dr.
Izdano: (2022-01-01)

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
od: Lindsay T. Fourman, i dr.
Izdano: (2020-08-01)

Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis
od: Philipp Bernhardt, i dr.
Izdano: (2018-02-01)

Hepatic Steatosis, Carbohydrate Intake, and Food Quotient in Patients with NAFLD
od: Concepcion Gonzalez, i dr.
Izdano: (2013-01-01)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
od: Laurens A. vanKleef, i dr.
Izdano: (2022-09-01)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
od: Shu Niu, i dr.
Izdano: (2022-12-01)

HEPATIC SOD1 GENE EXPRESSION CHANGES IN THE NAFLD PATHOGENESIS IN OBESITY
od: A. A. Komar, i dr.
Izdano: (2021-10-01)

Insulin secretion, insulin sensitivity, and hepatic insulin extraction in first-degree relatives of type 2 diabetic patients
od: W.P. Pimenta, i dr.
Izdano: (2003-03-01)

Hepatic Phospholipid Remodeling Modulates Insulin Sensitivity and Systemic Metabolism
od: Ye Tian, i dr.
Izdano: (2023-06-01)

The pseudokinase MLKL regulates hepatic insulin sensitivity independently of inflammation
od: Haixia Xu, i dr.
Izdano: (2019-05-01)

Dietary fat and insulin sensitivity.
od: Frayn, K, i dr.
Izdano: (2010)

Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway
od: Tong J, i dr.
Izdano: (2022-10-01)

Lessening hepatic injury in cholestatic liver by optimal dietary docosahexaenoic acid supplementation in rats
od: Guan-Yeu Diau, i dr.
Izdano: (2018-01-01)

Docosahexaenoic acid impairs the maturation of very low density lipoproteins in rat hepatic cells
od: Vatsala Maitin, i dr.
Izdano: (2014-01-01)

Hepatic circadian-clock system altered by insulin resistance, diabetes and insulin sensitizer in mice.
od: Huey-Ling Tseng, i dr.
Izdano: (2015-01-01)

HIV infection significantly reduces lipoprotein lipase which remains low after 6 months of antiretroviral therapy
od: Boothby, M, i dr.
Izdano: (2008)

NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
od: Simona Cernea
Izdano: (2024-02-01)

Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD
od: Kwazi Gabuza, i dr.
Izdano: (2024-01-01)

Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD.
od: Kwazi Gabuza, i dr.
Izdano: (2024-01-01)

Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
od: Man Wang, i dr.
Izdano: (2022-10-01)

Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example.
od: Sandra Page, i dr.
Izdano: (2013-01-01)

Hepatic fatty acid partitioning.
od: Hodson, L, i dr.
Izdano: (2011)

Hepatic fatty acid partitioning
od: Hodson, L, i dr.
Izdano: (2011)

A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD.
od: William B Ashworth, i dr.
Izdano: (2016-09-01)

Managing NAFLD in Type 2 Diabetes: the effect of lifestyle interventions
od: Parry, S, i dr.
Izdano: (2020)